Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 2 Chemotherapy planned at inclusion for the ST cohort (analysis population, N = 1174)*

From: Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study)

Planned CT regimen, n (%) Breast (n = 356) Lung (n = 280) GI: colorectal (n = 103) GI: non-colorectal (n = 72) GYN: ovarian (n = 72) GYN: non-ovarian (n = 39) Head & neck (n = 105) Prostate (n = 66) Other (n = 81) Total (N = 1174)
Adjuvant/neoadjuvant 260 (73.0) 47 (16.8) 22 (21.4) 12 (16.7) 28 (38.9) 7 (17.9) 39 (37.1) 2 (3.0) 23 (28.4) 440 (37.5)
Metastatic 95 (26.7) 198 (70.7) 80 (77.7) 59 (81.9) 41 (56.9) 30 (76.9) 53 (50.5) 64 (97.0) 56 (69.1) 676 (57.6)
Other 1 (0.3) 35 (12.5) 1 (1.0) 1 (1.4) 3 (4.2) 2 (5.1) 13 (12.4) 0 (0) 2 (2.5) 58 (4.9)
First-line 249 (69.9) 173 (62.2) 56 (54.4) 43 (59.7) 35 (48.6) 22 (56.4) 70 (66.7) 15 (22.7) 55 (67.9) 718 (61.3)
≥ Second-line 107 (30.1) 105 (37.8) 47 (45.6) 29 (40.3) 37 (51.4) 17 (43.6) 35 (33.3) 51 (77.3) 26 (32.1) 454 (38.7)
Missing data 0 2 0 0 0 0 0 0 0 2
Anthracyclines 227 (63.8) 2 (1.1)
Taxanes (w/o platinum) 82 (23.0) 36 (12.9) 1 (1.2)
Platinum (carboplatin or cisplatin) 16 (4.5) 219 (78.2) 30 (76.9) 4 (6.1)
No platinum (any cytotoxic regimen) 62 (93.9)
Bi or tri-therapy with 5-FU 143 (81.7)
Carboplatin (alone or combined) 56 (77.8) 23 (21.9) 25 (30.9)
Cisplatin (alone or combined) 4 (5.6) 70 (66.7) 35 (43.2)
Others 31 (8.7) 25 (8.9) 30 (17.1) 12 (16.7) 9 (23.1) 12 (11.4) 20 (24.7)
  1. *Some patients had missing data
  2. Other ST cohorts include urological outside prostate, sarcoma, thymic carcinoma, skin, bone, unknown primary, multiple independent sites
  3. CT chemotherapy, 5-FU 5-fluorouracil, GI gastrointestinal, GYN gynaecological, ST solid tumour